Two Vanguard bond funds receive top marks. Two HealthShares funds don't.

Glaxo may face a tough sell with newly approved Treximet; additional feedback on Elan, and more.

Isis continues to climb after announcing a Genzyme partnership.

Failing a phase III trial is never a good thing. Don't believe a CEO's attempt to spin it otherwise.

Skeptics of Nastech's nasal spray have gotten their due.

As someone who works a lot on cruise ships, I put Royal Caribbean's new internet to the test.

The troubled retailer has taken another major step to try to stave off closure.

GM blasted Street profit forecasts with adjusted earnings of $2.12 per share on revenues of $43.1 billion.

Wall Street is set to extend the S&P 500's solid January gains Tuesday as investors sort through a wave of corporate earnings ahead of tomorrow's crucial Fed rate decision.